Widespread biochemical correction of murine mucopolysaccharidosis type VII pathology by liver hydrodynamic plasmid delivery

Gene Therapy

Volumn 16, Issue 6, 2009, Pages 746-756

  Richard, M ^a,b,c,d   Arfi, A ^a,b,c,d   Seguin, J ^a,b,c,d   Gandolphe, C ^a,b,c,d   Scherman, D ^a,b,c,d  

^a INSERM   (France)

^b UMR8151   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d PSL RESEARCH UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; BETA GLUCURONIDASE; BETA N ACETYLHEXOSAMINIDASE; COMPLEMENTARY DNA; GLYCOSAMINOGLYCAN; PLASMID VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTROPORATION; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME RELEASE; GENE EXPRESSION; GENE REPLACEMENT THERAPY; HEART; HYDRODYNAMICS BASED TRANSFECTION; INTERMETHOD COMPARISON; KIDNEY; LIVER; LIVER DIRECTED TRANSFER; LUNG; MOUSE; MUCOPOLYSACCHARIDOSIS TYPE 7; MUSCLE; MUSCLE ELECTROTRANSFER; NONHUMAN; PRIORITY JOURNAL; SPLEEN; SYSTEMIC CIRCULATION; TARGET ORGAN;

ANIMALS; BONE MARROW; BRAIN; DISEASE MODELS, ANIMAL; DNA, COMPLEMENTARY; ELECTROPORATION; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GLYCOSAMINOGLYCANS; GLYCOSIDE HYDROLASES; INJECTIONS, INTRAVENOUS; LIVER; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MUCOPOLYSACCHARIDOSIS VII; MUSCLE, SKELETAL; ORGAN SPECIFICITY; PLASMIDS; RNA, MESSENGER; SPLEEN; TIME FACTORS; TISSUE DISTRIBUTION; TRANSGENES;

ANIMALIA; MURINAE; MUS;

EID: 67349241973     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2009.36     Document Type: Article

References (51)

1. Neufeld EF, Muenzer J. The mucopolysaccharidosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds). Metabol Mol Bases Inherit Dis. MacGraw-Hill: New York, 2001, pp 3421-3452.
2. Birkenmeier EH, Davisson MT, Beamer WG, Ganschow RE, Vogler CA, Gwynn B et al. Murine mucopolysaccharidosis type VII. Characterization of a mouse with beta-glucuronidase deficiency. J Clin Invest 1989; 83: 1258-1266.
3. Vogler C, Barker J, Sands MS, Levy B, Galvin N, Sly WS et al. Murine mucopolysaccharidosis VII: Impact of therapies on the phenotype, clinical course, and pathology in a model of a lysosomal storage disease. Pediatr Dev Pathol 2001; 4: 421-433.
4. Vogler C, Levy B, Galvin N, Lessard M, Soper B, Barker J et al. Early onset of lysosomal storage disease in a murine model of mucopolysaccharidosis type VII: Undegraded substrate accumulates in many tissues in the fetus and very young MPS VII mouse. Pediatr Dev Pathol 2005; 8: 453-462.
5. Neufeld EF. Lysosomal storage diseases. Annu Rev Biochem 1991; 60: 257-280.
6. Watson GL, Sayles JN, Chen C, Elliger SS, Elliger CA, Raju NR et al Treatment of lysosomal storage disease in MPS VII mice using a recombinant adeno-associated virus. Gene Therapy 1998; 5: 1642-1649.
7. Daly TM, Sands MS. Gene therapy for lysosomal storage diseases. Expert Opin Investig Drugs 1998; 7: 1673-1682.
8. Moullier P, Bohl D, Heard JM, Danos O. Correction of lysosomal storage in the liver and spleen of MPS VII mice by implantation of genetically modified skin fibroblasts. Nat Genet 1993; 4: 154-159.
9. Sands MS, Vogler C, Kyle JW, Grubb JH, Levy B, Galvin N et al. Enzyme replacement therapy for murine mucopolysaccharidosis type VII. J Clin Invest 1994; 93: 2324-2331.
10. Wolfe JH, Sands MS, Harel N, Weil MA, Parente MK, Polesky AC et al Gene transfer of low levels of beta-glucuronidase corrects hepatic lysosomal storage in a large animal model of mucopolysaccharidosis VII. Mol Ther 2000; 2: 552-561.
11. Donsante A, Levy B, Vogler C, Sands MS. Clinical response to persistent, low-level beta-glucuronidase expression in the murine model of mucopolysaccharidosis type VII. J Inherit Metab Dis 2007; 30 227-238.
12. Sands MS, Davidson BL. Gene therapy for lysosomal storage diseases. Mol Ther 2006; 13: 839-849.
13. Cheng SH, Smith AE. Gene therapy progress and prospects: Gene therapy of lysosomal storage disorders. Gene Therapy 2003; 10: 1275-1281.
14. Mir LM, Bureau MF, Gehl J, Rangara R, Rouy D, Caillaud JM et al. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 1999; 96: 4262-4267.
15. Scherman D. Towards non-viral gene therapy. Bull Acad Natl Med 2001; 185: 1683-1697.
16. Suda T, Liu D. Hydrodynamic gene delivery: Its principles and applications. Mol Ther 2007; 15: 2063-2069.
17. Herweijer H, Wolff JA. Gene therapy progress and prospects: Hydrodynamic gene delivery. Gene Therapy 2007; 14: 99-107.
18. Aronovich EL, Bell JB, Belur LR, Gunther R, Koniar B, Erickson DC et al. Prolonged expression of a lysosomal enzyme in mouse liver after sleeping beauty transposon-mediated gene delivery: Implications for non-viral gene therapy of mucopolysaccharidoses. J Gene Med 2007; 9: 403-415.
19. Kay MA, Baley P, Rothenberg S, Leland F, Fleming L, Ponder KP et al Expression of human alpha 1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes. Proc Natl Acad Sci USA 1992; 89: 89-93.
20. Snyder RO, Miao CH, Patijn GA, Spratt SK, Danos O, Nagy D et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997; 16: 270-276.
21. Birkenmeier EH, Barker JE, Vogler CA, Kyle JW, Sly WS, Gwynn B et al Increased life span and correction of metabolic defects in murine mucopolysaccharidosis type VII after syngeneic bone marrow transplantation. Blood 1991; 78: 3081-3092.
22. Xu L, Mango RL, Sands MS, Haskins ME, Ellinwood NM, Ponder KP. Evaluation of pathological manifestations of disease in mucopolysaccharidosis VII mice after neonatal hepatic gene therapy. Mol Ther 2002; 6: 745-758.
23. Ross CJ, Bastedo L, Maier SA, Sands MS, Chang PL. Treatment of a lysosomal storage disease, mucopolysaccharidosis VII, with microencapsulated recombinant cells. Hum Gene Ther 2000; 11: 2117-2127.
24. Bettan M, Emmanuel F, Darteil R, Caillaud JM, Soubrier F, Delaere P et al. High-level protein secretion into blood circulation after electric pulse-mediated gene transfer into skeletal muscle. Mol Ther 2000; 2: 204-210.
25. Raben N, Lu N, Nagaraju K, Rivera Y, Lee A, Yan B et al. Conditional tissue-specific expression of the acid alpha-glucosidase (GAA) gene in the GAA knockout mice: Implications for therapy. Hum Mol Genet 2001; 10: 2039-2047.
26. Tessitore A, Faella A, O'Malley T, Cotugno G, Doria M, Kunieda T et al. Biochemical, pathological, and skeletal improvement of mucopolysaccharidosis VI after gene transfer to liver but not to muscle. Mol Ther 2008; 16: 30-37.
27. Martin-Touaux E, Puech JP, Château D, Emiliani C, Kremer EJ, Raben N et al. Muscle as a putative producer of acid alphaglucosidase for glycogenosis type II gene therapy. Hum Mol Genet 2002; 11: 1637-1645.
28. Takahashi H, Hirai Y, Migita M, Seino Y, Fukuda Y, Sakuraba H et al Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer. Proc Natl Acad Sci USA 2002; 99: 13777-13782.
29. Naffakh N, Pinset C, Montarras D, Li Z, Paulin D, Danos O et al. Long-term secretion of therapeutic proteins from genetically modified skeletal muscles. Hum Gene Ther 1996; 7: 11-21.
30. Kreiss P, Bettan M, Crouzet J, Scherman D. Erythropoietin secretion and physiological effect in mouse after intramuscular plasmid DNA electrotransfer. J Gene Med 1999; 1: 245-250.
31. Tomanin R, Friso A, Alba S, Piller Puicher E, Mennuni C, La Monica N et al. Non-viral transfer approaches for the gene therapy of mucopolysaccharidosis type II (Hunter syndrome). Acta Paediatr Suppl 2002; 91: 100-104.
32. Sferra TJ, Backstrom K, Wang C, Rennard R, Miller M, Hu Y et al. Widespread correction of lysosomal storage following intrahepatic injection of a recombinant adeno-associated virus in the adult MPS VII mouse. Mol Ther 2004; 10: 478-491.
33. Daly TM, Lorenz RG, Sands MS. Abnormal immune function in vivo in a murine model of lysosomal storage disease. Pediatr Res 2000; 47: 757-762.
34. Chen ZY, Riu E, He CY, Xu H, Kay MA. Silencing of episomal transgene expression in liver by plasmid bacterial backbone DNA is independent of CpG methylation. Mol Ther 2008; 16: 548-556.
35. Hodges BL, Taylor KM, Joseph MF, Bourgeois SA, Scheule RK. Long term transgene expression from plasmid DNA gene therapy vectors is negatively affected by CpG dinucleotides. Mol Ther 2004; 10: 269-278.
36. Daly TM, Vogler C, Levy B, Haskins ME, Sands MS. Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. Proc Natl Acad Sci USA 1999; 96: 2296-2300.
37. Urayama A, Grubb JH, Sly WS, Banks WA. Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier. Proc Natl Acad Sci USA 2004; 101: 12658-12663.
38. Urayama A, Grubb JH, Sly WS, Banks WA. Mannose 6-phosphate receptor-mediated transport of sulfamidase across the blood-brain barrier in the newborn mouse. Mol Ther 2008; 16: 1261-1266.
39. Vogler C, Levy B, Grubb JH, Galvin N, Tan Y, Kakkis E et al. Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc Natl Acad Sci USA 2005; 102: 14777-14782.
40. Dunder U, Kaartinen V, Valtonen P, Väänänen E, Kosma VM, Heisterkamp N et al. Enzyme replacement therapy in a mouse model of aspartylglycosaminuria. FASEB J 2000; 14: 361-367.
41. Matzner U, Herbst E, Hedayati KK, Lüllmann-Rauch R, Wessig C, Schröder S et al. Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy. Hum Mol Genet 2005; 14: 1139-1152.
42. Zhang X, Dong X, Sawyer GJ, Collins L, Fabre JW. Regional hydrodynamic gene delivery to the rat liver with physiological volumes of DNA solution. J Gene Med 2004; 6: 693-703.
43. Fabre JW, Grehan A, Whitehorne M, Sawyer GJ, Dong X, Salehi S et al Hydrodynamic gene delivery to the pig liver via an isolated segment of the inferior vena cava. Gene Ther 2008; 15: 452-462.
44. Jacobs F, Snoeys J, Feng Y, Van Craeyveld E, Lievens J, Armentano D et al. Direct comparison of hepatocyte-specific expression cassettes following adenoviral and nonviral hydrodynamic gene transfer. Gene Therapy 2008; 15: 594-603.
45. Darquet AM, Rangara R, Kreiss P, Schwartz B, Naimi S, Delaère P et al. Minicircle: An improved DNA molecule for in vitro and in vivo gene transfer. Gene Therapy 1999; 6: 209-218.
46. Wooddell CI, Reppen T, Wolff JA, Herweijer H. Sustained liverspecific transgene expression from the albumin promoter in mice following hydrodynamic plasmid DNA delivery. J Gene Med 2008; 10: 551-563.
47. Argyros O, Wong SP, Niceta M, Waddington SN, Howe SJ, Coutelle C et al. Persistent episomal transgene expression in liver following delivery of a scaffold/matrix attachment region containing non-viral vector. Gene Therapy 2008; 15: 1593-1605.
48. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Therapy 1999; 6 1258-1266.
49. Zhang G, Budker V, Wolff JA. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 1999; 10: 1735-1737.
50. Wolfe JH, Sands MS. Murine mucopolysaccharidosis type VII: A model system for somatic gene therapy of the central nervous system. In: Enquist PR, Enquist LW (eds). Protocols for Gene Transfer in Neuroscience: Toward Gene Therapy of Neurologic Disorders. Wiley: Essex, 1996, pp 263-274.
51. Kyle JW, Grubb JH, Galvin N, Vogler C. Beta-glucuronidase (GUS) assay in animal tissue. In: Gallagher SR (ed). GUS Protocols: Using the GUS gene as a Reporter of Gene Expression. Academic Press: San Diego, 1992, pp 189-203.